CXCL8 and neoplasm: Furthermore, a monoclonal antibody that neutralizes IL-8, HuMax-IL8, reverted mesenchymal phenotype in claudin-low TNBC models in vitro and in vivo, and decreased the recruitment of tumor-promoting polymorphonuclear myeloid-derived suppressor cells at the tumor site in xenografts.